grant
Mitigating Diabetic Ketoacidosis in People with T1D and Chronic Kidney Disease on an SGLT1&2 Inhibitor: Ketosis Risk Factor Determination and Incorporation into an Enhanced Glucose Ketone Report
Organization HEALTHPARTNERS INSTITUTELocation Bloomington, UNITED STATESPosted 1 Sept 2025Deadline 31 Aug 2028
NIHUS FederalResearch GrantFY2025Adult-Onset Diabetes MellitusBrittle Diabetes MellitusCarbohydratesCardiac DiseasesCardiac DisordersCaringChronic Kidney FailureChronic Renal DiseaseChronic Renal FailureClinicalClinical TrialsCo-TransportersComprehensive Health CareConsensusContinuous Glucose MonitorD-GlucoseDataData ReportingDevelopmentDextroseDiabetes MellitusDiabetes preventionDiabetic AcidosisDiabetic KetoacidosisDiabetic KetosisDisease ProgressionDoseDrugsESKDESRDEarly DiagnosisEarly identificationEnd stage renal failureEnd-Stage Kidney DiseaseEnd-Stage Renal DiseaseEnsureEvaluationFundingFutureGenerationsGlomerular Filtration RateGlucoseGoalsHealthHeart DiseasesHumulin RIDDMIncidenceIndividualInsulinInsulin-Dependent Diabetes MellitusIntakeInternationalInterviewInvestigatorsJuvenile-Onset Diabetes MellitusKetonesKetosisKetosis-Prone Diabetes MellitusKetosis-Resistant Diabetes MellitusKidneyKidney DiseasesKidney Urinary SystemLeadershipManufacturerMaturity-Onset Diabetes MellitusMedicationMethodsMinnesotaMonitorNIDDKNIDDMNa elementNational Institute of Diabetes and Digestive and Kidney DiseasesNephropathyNon-Insulin Dependent DiabetesNon-Insulin-Dependent Diabetes MellitusNoninsulin Dependent DiabetesNoninsulin Dependent Diabetes MellitusNovolin ROutcomePatient PreferencesPatientsPersonsPharmaceutical PreparationsPlayPopulationPreventative strategyPrevention strategyPreventive strategyProviderRegular InsulinRenal DiseaseRenal functionReportingResearchResearch PersonnelResearchersRiskRisk FactorsRoleSafetySiteSlow-Onset Diabetes MellitusSodiumStable Diabetes MellitusStandardizationStructureSudden-Onset Diabetes MellitusSystemT1 DMT1 diabetesT1DT1DMT2 DMT2DT2DMTechnologyTimeType 1 Diabetes MellitusType 1 diabetesType 2 Diabetes MellitusType 2 diabetesType I Diabetes MellitusType II Diabetes MellitusType II diabetesadult onset diabetesbehavior changeblood glucose regulationcardioprotectantcardioprotectioncardioprotectivechronic kidney diseaseclinical relevanceclinically relevantcomprehensive carecontinuous blood glucose monitorcontinuous blood sugar monitorcontinuous glucose measurementcontinuous sugar monitordata representationdata representationsdata visualizationdevelopmentaldiabetesdiabetes mellitus therapydiabetes therapydiabetic ketoacidoticdietarydrug/agentearly detectionglucose controlglucose homeostasisglucose regulationglycemic controlheart disorderhigh riskimprovedinhibitorinhibitor druginhibitor therapeuticinhibitor therapyinjury to the vasculatureinsulin dependent diabetesinsulin dependent type 1juvenile diabetesjuvenile diabetes mellitusketosis prone diabetesketosis resistant diabeteskidney disorderkidney functionmaturity onset diabetesnew drug treatmentsnew drugsnew pharmacological therapeuticnew therapeuticsnew therapynext generation therapeuticsnovelnovel drug treatmentsnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel therapeuticsnovel therapyopen labelopen label studypatient subclasspatient subclusterpatient subgroupspatient subpopulationspatient subsetspatient subtypespreventpreventingprogression riskprospectiveprotective effectrenalrenal disorderrisk mitigationshared decision makingsocial rolesymportertype 2 DMtype I diabetestype II DMtype one diabetestype two diabetesusabilityvascular injury
Description preview
Project Summary
It is estimated that 1.8 million people in the U.S. have type 1 diabetes (T1D) and of these, at least 20% have
chronic kidney disease (CKD). Sodium-glucose cotransporter inhibitors (SGLT2i) and similar medications
improve glycemic control and are cardioprotective and kidney protective. However, in trials of SGLT2i as an
adjunct to…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click